Revenue GrowthSustained top-line expansion (~36% TTM) signals successful commercial traction for Nevisense. Durable revenue growth helps scale the installed base, increases recurring consumable pull-through, and provides a structural runway to leverage fixed-costs and improve long-term profitability if sustained.

Product-Level MarginsHigh gross margins (~66% TTM) indicate strong unit economics for the Nevisense platform and consumables. This margin cushion is durable, allowing the company to invest in sales/clinical adoption while preserving gross profit as volumes rise, aiding a sustainable path toward operating leverage.

Low Financial LeverageVery low debt (debt-to-equity ~0.01) lowers solvency and interest-rate risk, preserving strategic optionality. Structurally, low leverage reduces fixed financial obligations and gives management flexibility to raise capital on favorable terms or prioritize investment in commercialization without heavy near-term interest burdens.

Bears Say

Deep Operating And Net LossesExtremely negative operating and net margins show the cost base far exceeds revenue today. These structural losses erode equity and imply the company must materially improve margins or scale revenue quickly to reach sustainable profitability; otherwise losses will persist as a long-term drag.

Severe Cash BurnTrailing-twelve-month operating and free cash flow around -76M indicates persistent negative cash generation. This structural cash burn makes the business dependent on external financing, increases dilution risk, and constrains the firm's ability to fund commercialization and R&D from internal cash flow.

Negative Returns And Equity ErosionA deeply negative ROE (~-249%) signals ongoing shareholder value destruction and indicates current operations fail to generate returns on invested capital. Over months this raises the probability of dilutive capital raises and limits capacity to self-fund growth, pressuring long-term financial stability.

SciBase Holding AB News

5J3 Upcoming Earnings Report: What to Expect?

SciBase Holding AB (5J3) is scheduled to report 4th quarter earnings on 02/25/2025. Regarding Q4 estimates, Wall Street...

12M ago

5J3

SciBase Holding AB (5J3) Q3 Earnings Cheat Sheet

SciBase Holding AB (5J3) is scheduled to report 3rd quarter earnings on 11/12/2024. Regarding Q3 estimates, Wall Street...

1y ago

5J3

Is 5J3 a Buy, Before Earnings?

SciBase Holding AB (5J3) is scheduled to report 2nd quarter earnings on 08/21/2024. Regarding Q2 estimates, Wall Street...

1y ago

5J3

SciBase Holding AB (5J3) Q2 Earnings Cheat Sheet

SciBase Holding AB (5J3) is scheduled to report 2nd quarter earnings on 08/18/2023. Regarding Q2 estimates, Wall Street...

3y ago

5J3

SCIB FAQ

What was SciBase Holding AB’s price range in the past 12 months?

SciBase Holding AB lowest stock price was kr0.17 and its highest was kr0.50 in the past 12 months.

What is SciBase Holding AB’s market cap?

SciBase Holding AB’s market cap is kr218.69M.

When is SciBase Holding AB’s upcoming earnings report date?

SciBase Holding AB’s upcoming earnings report date is Feb 24, 2026 which is in 8 days.

How were SciBase Holding AB’s earnings last quarter?

SciBase Holding AB released its earnings results on Nov 07, 2025. The company reported -kr0.042 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.042.

Is SciBase Holding AB overvalued?

According to Wall Street analysts SciBase Holding AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SciBase Holding AB pay dividends?

SciBase Holding AB does not currently pay dividends.

What is SciBase Holding AB’s EPS estimate?

SciBase Holding AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does SciBase Holding AB have?

SciBase Holding AB has 828,365,200 shares outstanding.

What happened to SciBase Holding AB’s price movement after its last earnings report?

SciBase Holding AB reported an EPS of -kr0.042 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -19.184%.

Which hedge fund is a major shareholder of SciBase Holding AB?

Currently, no hedge funds are holding shares in SE:SCIB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

SciBase Holding AB

SciBase Holding AB (SCIB) is a Swedish medical technology company that specializes in developing innovative diagnostic solutions for skin cancer detection and monitoring. The company operates primarily in the healthcare sector, focusing on non-invasive and effective diagnostic tools. Its core products leverage advanced technology, particularly electrical impedance spectroscopy, to provide dermatologists and healthcare providers with real-time information to aid in the diagnosis of skin lesions, ultimately enhancing patient outcomes.